Loading
SAB Biotherapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Sullivan Eddie Joe, was filed 08 Dec 2023.
SAB Biotherapeutics, Inc.: what insiders have been doing
SAB Biotherapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 23 October 2025 to 23 October 2026, the disclosure feed for SAB Biotherapeutics, Inc. logged 4 filings by 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought SAB Biotherapeutics, Inc. shares on the open market in the past twelve months. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Compared with its exchange (3,167 companies, median 24 filings), a count of 4 filings is below the norm. Since 2021, the database holds 10 purchases and 1 sale by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at 13.3 m USD.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€4M
10 ops. · all time
Sell Volume
€1,894
1 ops. · all time
Since the insiders bought
- -43.1%Entry US$8.02 · Close at T+365 US$4.56
- -70.1%Entry US$9.40 · Close at T+365 US$2.81
- -70.1%Entry US$9.40 · Close at T+365 US$2.81
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.82
Analyst consensus
11 analystsUS$6.00Target US$11.64(+313%)US$16.00
Income statement
EBITDAUS$16.6M
Net incomeUS$13.3M0.0% margin
Valuation
PER (trailing)12.4x
PER (forward)-3.0x
P/Book1.1x
Beta0.58
Balance sheet & cash
Market capUS$256.6M
Total debtUS$6M
Free Cash Flow-US$45.7M
Debt / Equity2%
Profitability & ownership
ROE-11.3%
ROA-33.5%
% insiders0.7%
% institutions75.4%
Last declaration on 18 September 2026
Declarations59 total
473 sharesCommon StockSEC:0001193125-26-395552:0
988 sharesCommon StockSEC:0001193125-26-285722:0
988 sharesCommon StockSEC:0001193125-26-124231:0
988 sharesCommon StockSEC:0001193125-25-317688:0
1,740,000 shares@ US$1.75100.0% of flowCommon StockSEC:0001193125-25-226846:0
1,740,000 shares@ US$1.75100.0% of flowCommon StockSEC:0001012975-25-000592:0
1,977 sharesCommon StockSEC:0001193125-25-211490:0
1,179 sharesCommon StockSEC:0000950170-25-048551:0
9,072 sharesCommon StockSEC:0000950170-24-141672:0
1,740 shares@ US$0.8812.1% of flowCommon StockSEC:0000950170-23-068922:0
Canonical exit: 6 Mar 2024 (T+90)
5,000 shares@ US$0.90100.0% of flowCommon StockSEC:0000950170-23-067072:0
Canonical exit: 28 Feb 2024 (T+90)
11,000 shares@ US$0.8947100.0% of flowCommon StockSEC:0000950170-23-066901:0
Canonical exit: 27 Feb 2024 (T+90)
4,584,571 sharesCommon StockSEC:0001062993-23-021502:0
4,584,571 sharesCommon StockSEC:0000950170-23-066395:0
2,857,142 sharesCommon StockSEC:0000950170-23-066394:0
275,000 sharesCommon StockSEC:0001437749-23-006913:0
41,493 shares@ US$1.205100.0% of flowCommon StockSEC:0001209191-22-060440:0
82,987 shares@ US$1.205100.0% of flowCommon StockSEC:0001209191-22-060442:0
82,987 shares@ US$1.20592.9% of flowCommon StockSEC:0001209191-22-060501:0
10,000 shares@ US$0.72977.1% of flowCommon StockSEC:0001209191-22-049950:0
Canonical exit: 12 Dec 2022 (T+90)
14,000 shares@ US$0.736887.9% of flowCommon StockSEC:0001209191-22-049168:0
Canonical exit: 6 Dec 2022 (T+90)
300,000 shares0Common StockSEC:0001209191-22-034919:0
207,001 shares0Common StockSEC:0001209191-22-031398:1
299,002 shares0Common StockSEC:0001209191-22-031401:0
2,500,127 shares0Common StockSEC:0001209191-22-031398:0
25 of 59 declarations
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (ticker: SABSW) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. It is a clinical-stage biopharmaceutical business with a platform-driven strategy rather than a commercialized product portfolio, which makes it a classic development-stage name for investors looking at high-upside but higher-risk healthcare equities. The company is currently associated with Miami Beach, Florida, while its historical operating roots are tied to Sioux Falls, South Dakota. Founded in 2014, SAB Biotherapeutics was built around a proprietary approach to producing fully human polyclonal antibodies for serious diseases with substantial unmet medical need.
The company’s core competitive differentiator is its DiversitAb™ platform, designed to generate highly targeted, high-potency human immunoglobulins without relying on human plasma donors. That platform narrative is important from an equity-analysis perspective: SAB is not simply a single-asset story, but a technology platform that could, in theory, be applied across multiple therapeutic areas. In a competitive biotech landscape dominated by monoclonal antibodies, cell therapies, and conventional immunology pipelines, SAB’s approach aims to stand out through breadth of immune response and flexibility of development.
Read moreShow less
SAB’s lead program is SAB-142, a clinical-stage candidate being developed for autoimmune type 1 diabetes. Management has positioned it as a potentially disease-modifying and redosable immunotherapy, with the strategic objective of slowing disease progression rather than only managing symptoms. The company is also pursuing additional autoimmune opportunities, which provides pipeline optionality but also adds execution complexity. As with most small-cap clinical biotech companies, the investment case depends heavily on trial data, regulatory progress, manufacturing readiness, and ongoing access to capital.
From a geographic and market standpoint, SAB is a United States company whose commercial footprint remains primarily domestic and development-focused. Recent corporate activity has underscored both progress and financing needs. In March 2026, the company completed a public equity offering, and in April 2026 it announced a manufacturing services agreement with Emergent BioSolutions Canada, supporting future production and operational planning. SAB also reported additional Phase 1 data for SAB-142 in March 2026, including early signals around C-peptide preservation, a clinically meaningful biomarker that the market typically watches closely in type 1 diabetes development.
Overall, SAB Biotherapeutics is best viewed as a speculative NASDAQ-listed U.S. biotech with a differentiated antibody platform, a lead autoimmune diabetes asset, and meaningful long-term upside if its clinical and manufacturing execution continues to improve. At the same time, investors should recognize the usual development-stage risks: clinical uncertainty, regulatory hurdles, funding dependence, and potential dilution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
